- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior
therapies; one prior therapy must include anthracyclines and one must include
rituximab in combination with chemotherapy
- Relapsed/disease progression within 12 months after start of prior therapy and/or
secondary International Prognostic Index (sIPI) score greater than 1
- Eligible for autologous stem cell transplant (aSCT)
- Prior allogeneic hematopoietic stem cell transplant
- Within 6 months prior to test article: autologous transplant, treatment with anti-CD22
antibodies, radio-immunotherapy
- Veno-occlusive disease or sinusoidal obstruction syndrome, chronic liver disease,
systemic vasculitides, current or chronic hepatitis B or C infection